AHMED NADIM 4
4 · Cullinan Therapeutics, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Cullinan (CGEM) CEO Ahmed Nadim Receives Award of 828,000 Shares
What Happened
Ahmed Nadim, President, CEO and a director of Cullinan Therapeutics (CGEM), was granted 828,000 derivative shares on 2026-02-18. The Form 4 reports a $0.00 price and a total reported value of $0, indicating this was an equity award/option grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-18; Form 4 filed 2026-02-19 (timely filing).
- Transaction type: Grant / award of derivative securities (code A).
- Amount: 828,000 shares (derivative/option). Price reported: $0.00; reported value: $0.
- Vesting: Footnote F1 — underlying shares vest over four years, with 1/48th vesting in equal monthly installments through the fourth anniversary.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Filing timeliness: Filed the next day; not indicated as late.
Context
This was an equity award (derivative/option grant) to the CEO, not a market purchase or sale. The grant vests monthly over four years, so the shares/options are earned over time rather than delivered immediately. Such grants are commonly used for executive compensation and retention; they do not by themselves indicate immediate buying or selling of stock.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-18+828,000→ 828,000 totalExercise: $12.44Exp: 2036-02-18→ Common Stock (828,000 underlying)
Footnotes (1)
- [F1]The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.